DK1032672T3 - DNA19355-polypeptid, en tumornekrosefaktor-homolog - Google Patents

DNA19355-polypeptid, en tumornekrosefaktor-homolog

Info

Publication number
DK1032672T3
DK1032672T3 DK98958067T DK98958067T DK1032672T3 DK 1032672 T3 DK1032672 T3 DK 1032672T3 DK 98958067 T DK98958067 T DK 98958067T DK 98958067 T DK98958067 T DK 98958067T DK 1032672 T3 DK1032672 T3 DK 1032672T3
Authority
DK
Denmark
Prior art keywords
dna19355
necrosis factor
tumor necrosis
dna19355 polypeptide
factor homologue
Prior art date
Application number
DK98958067T
Other languages
English (en)
Inventor
Austin L Gurney
Scot A Marsters
Paul J Godowski
Avi J Ashkenazi
Robert Pitti
Kevin P Baker
Melanie R Mark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1032672T3 publication Critical patent/DK1032672T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98958067T 1997-11-18 1998-11-18 DNA19355-polypeptid, en tumornekrosefaktor-homolog DK1032672T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6563597P 1997-11-18 1997-11-18
US6966197P 1997-12-12 1997-12-12
PCT/US1998/024621 WO1999025834A1 (en) 1997-11-18 1998-11-18 Dna19355 polypeptide, a tumor necrosis factor homolog

Publications (1)

Publication Number Publication Date
DK1032672T3 true DK1032672T3 (da) 2009-04-27

Family

ID=26745805

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98958067T DK1032672T3 (da) 1997-11-18 1998-11-18 DNA19355-polypeptid, en tumornekrosefaktor-homolog

Country Status (12)

Country Link
US (4) US20020146389A1 (da)
EP (1) EP1032672B1 (da)
JP (2) JP4485049B2 (da)
AT (1) ATE419357T1 (da)
AU (1) AU760010B2 (da)
CA (1) CA2308365A1 (da)
DE (1) DE69840413D1 (da)
DK (1) DK1032672T3 (da)
ES (1) ES2320285T3 (da)
IL (1) IL135911A0 (da)
PT (1) PT1032672E (da)
WO (1) WO1999025834A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
WO2001040464A1 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
EP1212417B1 (en) * 1999-06-02 2008-04-30 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
WO2003006058A1 (en) * 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
US7087225B2 (en) * 2001-08-16 2006-08-08 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US20060058288A1 (en) * 2002-04-08 2006-03-16 Masayuki Ii Severe sepsis preventive therapeutic agent
US7618632B2 (en) * 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
WO2005007190A1 (en) * 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) * 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
US20070065889A1 (en) * 2004-12-02 2007-03-22 Roberts Bruce L Compositions and methods to diagnose and treat lung cancer
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
MX2017015260A (es) 2015-06-03 2018-02-19 Squibb Bristol Myers Co Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
US11787867B2 (en) 2020-03-06 2023-10-17 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
ATE412740T1 (de) * 1996-08-16 2008-11-15 Human Genome Sciences Inc Menschliches alpha-endokin
US5998171A (en) * 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha

Also Published As

Publication number Publication date
DE69840413D1 (de) 2009-02-12
US20020146389A1 (en) 2002-10-10
US20070072263A1 (en) 2007-03-29
ES2320285T3 (es) 2009-05-20
JP2001523459A (ja) 2001-11-27
US20040234498A1 (en) 2004-11-25
JP2010088448A (ja) 2010-04-22
ATE419357T1 (de) 2009-01-15
WO1999025834A1 (en) 1999-05-27
EP1032672B1 (en) 2008-12-31
EP1032672A1 (en) 2000-09-06
CA2308365A1 (en) 1999-05-27
US20060216270A1 (en) 2006-09-28
JP4485049B2 (ja) 2010-06-16
IL135911A0 (en) 2001-05-20
AU1418099A (en) 1999-06-07
AU760010B2 (en) 2003-05-08
PT1032672E (pt) 2009-04-02

Similar Documents

Publication Publication Date Title
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69535719D1 (de) Fas-antigenbindender ligand
TW428026B (en) Bifunctional protein, preparation and use
FI101720B1 (fi) Synteettisen DNA:n konstruointi ja sen käyttö suurten polypeptidien synteesissä
EP0575546A4 (en) Prad1 cyclin and its cdna
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE68905633D1 (de) Markierer der t-zelle aktivierung.
BG100771A (bg) Хематопоетичен протеин и материали и методи за неговото получаване
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
ATE286907T1 (de) Cytokinin-designiertes lerk-5
NL990034I1 (nl) DNA dat codeert voor humane tumor necrosis faktor en humane tumor necrosis faktor polypeptide.
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
DK0804558T3 (da) Tripeptidylaminopeptidase
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ATE424459T1 (de) Apo-3 ligand
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen
DE59712771D1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung